



**ADVITECH ANNOUNCES A REVISED AGREEMENT
WITH JOUAN BIOTECHNOLOGIES AND A CHANGE OF DISTRIBUTOR FOR
THE U.S. MARKET**

TSX VENTURE EXCHANGE: AVI

FOR IMMEDIATE RELEASE

JOUAN BIOTECHNOLOGIES

QUÉBEC CITY - September 27, 2006 – Advitech inc. (TSX-V: AVI) announces today the signing of a revised agreement with Jouan Biotechnologies covering the royalties to be paid by Advitech to Jouan Biotechnologies on the international sales of Dermylex™. The initial licensing agreement, signed in 2003, stipulated minimum royalty fees payable to Jouan Biotechnologies by Advitech for the first three years of the agreement, including additional royalty fees corresponding to net sales percentage generated by Advitech when commercializing Dermylex™. In August 2006, Advitech finalized the minimum royalty fees payment and negotiated a new agreement ending in 2013, reducing the percentage on the minimum royalty fees on Dermylex™ sales to be paid to Jouan by Advitech. Advitech has also retained the possibility of extending the duration of the agreement until the expiry date of the last Foreign Patent underlying the licensed technology by Jouan in favour of Advitech.

DISTRIBUTION IN THE U.S.

Advitech has also announces the end of its discussions with PhotoMedex, the U.S. corporation with which an agreement of principle was signed in January 2006, for the distribution of Dermylex™ on the U.S. market. That corporation could not meet the required conditions for concluding a definitive agreement. Advitech is currently negotiating with new potential partners (and already has market tests running in the United States). It intends to secure a definitive agreement for the U.S. market by the first quarter of 2007.

Advitech has, in addition, signed a consultation contract with Joe Contorno, former President and Chief Executive Officer of Doctor's Dermatologic Formula, in New York City, to assist Advitech in its ongoing discussions with U.S. partners, and to follow market developments. "Joe Contorno has vast and profitable experience in the development of companies similar to Advitech on the U.S. market and his expertise has already generated certain opportunities for Advitech," specified Renaud Beauchesne, Advitech's President and Chief Executive Officer.

ABOUT DERMYLEX™

Dermylex™, developed by Advitech, is an oral natural health product relieving mild to moderate psoriasis symptoms. Its efficacy has been clinically proven by two clinical trials, one of them multi-center, double-blind and placebo-controlled, for 112 days and on 84 patients, confirming Dermylex™'s efficacy and safety for mild to moderate psoriasis. Dermylex™ is currently available in Canada. For more information, please visit the www.dermylex.ca website.

ABOUT ADVITECH

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immuned Mediated Inflammatory Disorders (IMID), such as psoriasis and inflammatory bowel diseases. Advitech's common shares are listed on the TSX Venture Exchange under symbol AVI. The number of common shares outstanding is 54,799,818.

-30-

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ significantly from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.

Renaud Beauchesne, MBA
President and Chief Executive Officer
(418) 686-7498, ext. 228
info@advitech.com
www.advitech.com